Close Menu

NEW YORK (GenomeWeb) – T2 Biosystems reported after the close of the market on Monday that its fourth quarter revenues fell nearly 10 percent, despite a 69 percent increase in product revenues driven by an increase in sales of its T2Candida panel.

For the three-month period ended Dec. 31, T2's revenues fell to $910,000 from $1.0 million in the same period the year before, missing the Wall Street consensus estimate for revenues of $1.4 million.

Product revenues rose to $579,000 from $343,000 in Q4 2015. Meanwhile, the company reported research revenues of $331,000.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The UK and the European Union have come to a sticking point in the negotiation of how the UK might remain involved in the Horizon Europe research program, the Guardian reports.

The New York Times reports that experts pushed during a meeting of an FDA advisory board for the agency to require more safety data from SARS-CoV-2 vaccine trials.

The Washington Post reports Moderna expects that it will have enough data on its candidate SARS-CoV-2 vaccine to submit to regulatory authorities by mid-November.

In Science this week: ANXA11 variants affect calcium homeostasis and stress granule disassembly in ALS, and more.